Navigation Links
Steve Jobs' Death Highlights Critical Need for New Therapies for Pancreatic Cancer
Date:10/10/2011

WHITE PLAINS, N.Y., Oct. 10, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) joins in grieving the untimely death of Apple Co-Founder Steve Jobs from pancreatic cancer. Jobs' death comes on the heels of other high profile deaths from the disease - those of Nobel Laureate Ralph Steinman last week, and actor Patrick Swayze two years ago.

(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO)

These deaths bring to light a disease with an extremely poor prognosis for which there are limited therapies. The five-year relative survival rate for this patient population is less than five percent.

But better news may come in the form of therapies originally approved to treat patients with blood cancers. Roughly 50 percent of the cancer drugs approved by the Food & Drug Administration (FDA) in the past decade were first approved to treat patients with a form of blood cancer. Many of these drugs are now commonly used to help additional patients and some are showing promise against certain solid tumors, including pancreatic cancer.

LLS helped advance Revlimid®, a drug that can enhance anti-cancer immune responses and block cancer-feeding blood supplies. It is FDA-approved for patients diagnosed with myeloma or myelodysplastic syndromes.  Based on exciting laboratory results, Revlimid is now being tested with a standard chemotherapy in clinical trials for pancreatic cancer patients.

Likewise, LLS funded research advanced Zolinza®, a first-in-class enzyme-targeting drug that can kill cancer cells by reprogramming critical gene activities. Zolinza is FDA-approved to treat certain lymphoma patients, and being tested in clinical trials for pancreatic cancer patients.

"The passing of the visionary Steve Jobs was a truly sad occasion and his death has brought attention to a deadly cancer for which there are very limited options for patients," said LLS President and CEO John Walter. "But as with many other diseases, therapies originally developed to treat patients with blood cancer are showing real promise and we are hopeful that these advances will one day soon help patients with pancreatic cancer."

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

Andrea Greif
(914)821-8958
andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stevens researchers pioneer novel technique to make plasmonic nanogap arrays
2. ONR funds study of nanoscale wetting dynamics of superhydrophobic surfaces at Stevens
3. Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way"
4. Dr. Frank Fisher of Stevens selected for Fulbright specialist roster
5. Steven Seagal Asks For Russian PM Vladimir Putins Support in Immortality Research
6. Dr. Stefan Strauf of physics at Stevens receives NSF CAREER Award for quantum research
7. Biotech Guru G. Steven Burrill Offers his Predictions on What Lies Ahead for the Biotech Industry in 2011
8. Nanoimprint lithography NSF grant awarded to micro device lab at Stevens
9. Microfluidic devices advance 3-D tissue engineering at Stevens
10. Xiaoguang Meng receives honorary master of engineering from Stevens
11. AMTs EGM Passes All Resolutions and Strengthens Supervisory Board With Joseph Feczko, Steven Holtzman and Francois Meyer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... NEW YORK , May 26, 2016 ... industry, investors see value in this space. Today,s pre-market research ... Healthcare equities: Radius Health Inc. (NASDAQ: RDUS ), ... (NASDAQ: ARWR ), and Five Prime Therapeutics Inc. ... these stock technical briefings at: http://www.activewallst.com/ ...
(Date:5/26/2016)... ... May 26, 2016 , ... Kinder Scientific (KinderScientific.com), a ... that position the Company for the future. Kinder Scientific announces restructured ownership ... has been appointed Chairman of the Board, Curtis D. Kinghorn has been appointed ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lajollacooks4u has become a rising hotspot for ... one of its top attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm ... and intimate team-building experience. , Each event kicks off with an olive oil and ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Ankle ... plating options designed to address fractures of the distal tibia and fibula. This ... Acumed Ankle Plating System 3 is composed of seven plate families that span ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):